TCR-T Immunotherapy: The Challenges and Solutions

Frontiers in Oncology

Yating Liu²  Zhijian Han²  Futian Tang²  Yumin Li²  Fan Zhang²  Xin Yan²  Xiaoxia Zhang² 

[1] Department of Oncology, Lanzhou University Second Hospital, Lanzhou, China;Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China;

关键词: receptor-engineered T cell;    immunotherapy;    challenges;    solutions;    solid tumors;   

DOI  :  10.3389/fonc.2021.794183

来源: DOAJ

【 摘 要 】

T cell receptor-engineered T cell (TCR-T) therapy is free from the limit of surface antigen expression of the target cells, which is a potential cellular immunotherapy for cancer treatment. Significant advances in the treatment of hematologic malignancies with cellular immunotherapy have aroused the interest of researchers in the treatment of solid tumors. Nevertheless, the overall efficacy of TCR-T cell immunotherapy in solid tumors was not significantly high when compared with hematological malignancies. In this article, we pay attention to the barriers of TCR-T cell immunotherapy for solid tumors, as well as the strategies affecting the efficacy of TCR-T cell immunotherapy. To provide some reference for researchers to better overcome the impact of TCR-T cell efficiency in solid tumors.

【 授权许可】

Unknown